Clinical trials: MEASLES DISEASE
Meales-mumps-rubella Vaccine
MMR at 6 Months Trial
Randomised, double-blind clinical trial to test humoral and cellular immunogenicity, and potential in-direct beneficial effect of the MMRvaxpro-vaccine administered at 6 months of age
- Trial name
- NCT03780179
- Testing
- MMRvaxpro
- Where
- 2 sites in Denmark
- Volunteers
- 6,540 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Signs and Symptoms
Clinical Trial for Measles - Rubella Combined Vaccine (MRVAC) Produced by POLYVAC (Phase III)
The study is conducted to evaluate the safety and Immunogenicity of Measles-Rubella combined vaccine MRVAC produced by POLYVAC (phase 3) on Vietnamese volunteers and to demonstrate non-inferiority on the immunogenicity of MRVAC…
- Trial name
- NCT03713359
- Testing
- Trial arm (MRVAC), Control arm
- Volunteers
- 756 people, healthy volunteers welcome
- Sponsor
- Center for Research and Production of Vaccines and Biologicals, Vietnam
Varicella, Measles
Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)
Primary Objective: To demonstrate that ProQuad® can be administered concomitantly with a booster dose of Infanrix® hexa to healthy children 12 to 23 months of age without impairing either the antibody response rates to measles…
- Conditions
- Varicella, Measles, Mumps, Rubella
- Trial name
- NCT00432042
- Testing
- ProQuad®, Infanrix® hexa
- Where
- 50 sites in Germany, Italy
- Volunteers
- 955 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles, Mumps
Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines
The purpose of this study is to see if the MMR and chickenpox vaccines work as well in premature infants as in children that were carried to full term.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00138255
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Varicella, Rubella
Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM
The purpose of this study is to assess non-inferiority of two different vaccination regimens using GSK Biological's MMRV vaccine (two doses at 9 and 15 months) or Priorix™ (9 months) and one dose of MMRV vaccine (15 months) to…
- Conditions
- Varicella, Rubella, Mumps, Measles
- Trial name
- NCT00969436
- Testing
- GSK Biological's investigational MMRV vaccine 208136, Priorix™, Varilrix™
- Where
- 6 sites in India
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.
It is a clinicaltrial Phase III , randomized, double -blind , 4-arm (390 each one): This study will include 1560 children and will use 3 batches of vaccine produced by Bio - Manguinhos with viral bulk of GSK combined measles …
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT01991899
- Testing
- MMR Bio-Manguinhos, MMR GlaxoSmithKline
- Where
- Brazil
- Volunteers
- 1,560 people, healthy volunteers welcome
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Hepatitis A, Measles
Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)
Two doses each of Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella [Oka/Merck] Virus Vaccine Live will be given concomitantly or non-concomitantly.
- Conditions
- Hepatitis A, Measles, Mumps, Rubella
- Trial name
- NCT00326183
- Testing
- VAQTA®, ProQuad
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
This phase I/II trial studies the side effects and best dose of oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) infected mesenchymal stem cells and to see how well it works in treating patients with…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT02068794
- Testing
- Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
MEASLES DISEASE
Unravelling the Measles Paradox (MISIA)
The measles (MeV) paradox refers to an apparent contradiction: natural measles causes a transient but profound immune suppression putting patients at risk for opportunistic infections for years, while at the same time MeV…
- Trial name
- MISIA (NCT07267585)
- Where
- Netherlands
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
Measles
Early Two-dose Measles Vaccination Trial
The specific aims are to examine in Guinea-Bissau: whether the standard titre Schwarz (SW) or standard-titre Edmonston-Zagreb (EZ) measles vaccine will be the best vaccine strain for use in a routine one-dose measles vaccination…
- Trial name
- NCT00168558
- Testing
- Measles vaccine
- Where
- Guinea-Bissau
- Volunteers
- 5,879 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Measles Antibody Seroconversion, Rubella Antibody Seroconversion
Coadministration of Measles-rubella and Rotavirus Vaccines
The investigators aim to establish the non-inferiority of concomitant administration of measles-rubella and rotavirus vaccines to measles-rubella vaccine given alone in terms of measles seroconversion rates.
- Conditions
- Measles Antibody Seroconversion, Rubella Antibody Seroconversion, Rotavirus Geometric Mean Titer (GMT), Rotavirus Immunoglobulin A (IgA) Seropositivity
- Trial name
- NCT01700621
- Testing
- Rotarix vaccine, measles-rubella vaccine
- Where
- Bangladesh
- Volunteers
- 482 people, healthy volunteers welcome
- Sponsor
- PATH
Coronavirus (COVID-19)
Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?
The following two mechanisms that explain the ability of measles vaccine to cause partial protection against COVID-19. The first is that measles vaccine may increase the ability of the immune system to fight off pathogens other…
- Trial name
- NCT04445610
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Estrogen Receptor Negative, Estrogen Receptor Positive
Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer
This phase I trial studies the side effects and the best dose of viral therapy in treating patients with squamous cell carcinoma of the head and neck that has returned (come back) after a period of improvement or has spread to…
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, Head and Neck Squamous Cell Carcinoma, HER2/Neu Negative
- Trial name
- NCT01846091
- Testing
- Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Rubella, Varicella
Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine
Follow-up to evaluate the immunogenicity and safety of three production lots of GSK Biologicals' MMRV vaccine given as a two-dose schedule to healthy children in their second year of life, as compared to separate administration…
- Conditions
- Rubella, Varicella, Mumps, Measles
- Trial name
- NCT00406211
- Testing
- MMRV, MMR (Priorix®), Varicella (Varilrix®)
- Where
- 41 sites in Austria, Germany
- Volunteers
- 398 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Immunization Coverage, Vaccination
Increasing Measles Vaccination Coverage Through Supplementation With an SQ-LNS Incentive in Children Aged 6-23 Months
Provision of SQ-LNS also holds promise in incentivizing vaccination as well as other health services. The investigators will estimate 1) the effectiveness of a SQ-LNS mass supplementation program added to routine immunization…
- Conditions
- Immunization Coverage, Vaccination, Nutrition
- Trial name
- NCT06387511
- Testing
- Small-quantity lipid-based nutrition supplements (SQ-LNS) NutriVax, Sensitization on vaccination and on Infant and Young Child Feeding (IYCF) practices
- Where
- Nigeria
- Volunteers
- 3,814 people, healthy volunteers welcome
- Sponsor
- Alliance for International Medical Action
Chickenpox
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
This study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection.
- Trial name
- NCT06855160
- Testing
- Candidate varicella vaccine, Marketed varicella vaccine, MMR vaccine
- Where
- 22 sites in United States, Belgium and 5 more
- Volunteers
- 911 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles; Mumps; Rubella; Chickenpox, Measles
A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
The main purpose of this study is to assess immune response and safety of various potencies of a measles, mumps, rubella, and varicella (MMRVNS) vaccines given to healthy children of 4 to 6 years of age.
- Trial name
- NCT05630846
- Testing
- Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine
- Where
- 47 sites in United States, Colombia and 3 more
- Volunteers
- 801 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles Vaccine
Immunity Duration Study Eight Years After Vaccination of Children 12 to 23 Months With the Triple Viral Vaccine (Measles, Mumps and Rubella)
Several studies on the duration of immunity after the vaccine try to explain the cause of susceptibility to the measles virus even after the administration of 2 doses of the viral triple vaccine, based not only on the finding of…
- Trial name
- NCT05154097
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Covid19
Measles Vaccine in HCW
Till now, mortality reports among children below 9 years remains extremely low despite that the incidence of death toll is high and exceeding 50,000 patients among older population, One speculation for lower SARS infectivity is…
- Trial name
- MV-COVID19 (NCT04357028)
- Testing
- Measles-Mumps-Rubella Vaccine
- Where
- Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Kasr El Aini Hospital